RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABA\textsubscript{A} Receptor-\textgamma{2}

Yi-An Zhang\textsuperscript{1*}, Hai-Ning Liu\textsuperscript{2†}, Ji-Min Zhu\textsuperscript{2}, Dan-Ying Zhang\textsuperscript{2}, Xi-Zhong Shen\textsuperscript{2,3} and Tao-Tao Liu\textsuperscript{2*}

Abstract

Background: The mechanism of Nova1’s role in hepatocellular carcinoma has not been delineated. Also its interaction with GABA\textsubscript{A} receptor \gamma{2} in HCC is unveiled. This study is aimed to make it clear the distribution, prognostic value of GABA\textsubscript{A}R\gamma{2} in human hepatocellular carcinoma. And its role in HCC tumorigenesis under the regulation of its alternative splicing factor Nova1.

Methods: Immunohistochemistry staining was used to investigate the distribution and clinical significance of GABA\textsubscript{A}R\gamma{2} protein expression in hepatocellular carcinoma. In vivo tumorigenicity test was conducted in nude mice by regulation the expression of Nova1. Later, western blot and co-immunoprecipitation were carried out to verify the interaction between Nova1 and GABA\textsubscript{A}R\gamma{2} in HCC tissue.

Results: Immunohistochemical staining showed GABA\textsubscript{A}R\gamma{2} expression in HCC. Survival analysis showed intratumoral GABA\textsubscript{A}R\gamma{2} was an independent prognostic factor for overall survival (OS) and disease free survival (DFS). Up-regulation of Nova1 expression promotes subcutaneous HCC growth in nude mice and western blot showed the ectopic expression of Nova-1 restro-regulates the expression of GABA\textsubscript{A}R\gamma{2} and GABA. Protein level interaction of GABA\textsubscript{A}R\gamma{2} and Nova-1 was evidenced by co-immunoprecipitation.

Conclusions: Nova1 interacts with GABA\textsubscript{A}R\gamma{2} not only in CNS but also in HCC. Nova1’s potential mechanism as an oncogene may due to its interaction with GABA\textsubscript{A} R\gamma{2}. A better understanding of the mechanism of Nova1 for HCC progression provides a novel target for an optimal immunotherapy against this fatal malignancy.

Keywords: Nova1, GABA\textsubscript{A} Receptor-\gamma{2}, Oncogene, RNA binding protein

Background

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Although large efforts have been made to have a deeper insight into its pathogenesis and treatment, it is still one of the few cancers with a continued increase in incidence observed over these decades [1].

In recent years, the roles of RNA-binding proteins (RBPs) in the progression and prognosis of HCC have been delineate [2–4]. Nova-1, a neuron specific RNA binding protein, influences ligand-binding, signaltransducing and electrophysiological properties [5]. Our previous study demonstrated the expression of Nova-1 in HCC and proved that high expression of Nova-1 is associated with poor prognosis of HCC [6]. Previous researchers also found that Nova-1 regulates the alternative splicing of GABA\textsubscript{A} receptor \gamma{2} (GABA\textsubscript{A}R\gamma{2}) pre-mRNA in central nervous system [7]. GABA\textsubscript{A}R\gamma{2} belongs to the GABA receptor family. GABA\textsubscript{A} is most prevalent not only in central nervous system but also in peripheral tissues [8]. Activation of GABA\textsubscript{A} receptors
resulted in increased chloride ion influx and hyperpolarization of cell membranes by diminishing the chance of a successful action potential occurring [8]. Recently, lots of reports have pointed out that the relationship between decreased hepatocyte membrane potential and proliferation of hepatocellular carcinoma. Related receptors include GABA_A receptor-β3 [9], GABA_A receptor-α3 [10], and GABA_B Receptor family [11]. However, the potential effects of GABA_γ2 on tumor proliferation has not been mentioned yet.

In this study we first conducted a tumorigenicity test in nude mice and found that Nova1 could improve tumor growth in vivo. The interaction between Nova1 and GABA_γ2 was further confirmed by co-immunoprecipitation. Later, verification of the GABA_γ2 expression in hepatocellular carcinoma and its relations with HCC prognosis were also investigated. After all we demonstrated that Nova1 could promote cell proliferation in vivo, its potential mechanism as an oncogene may related to its interaction with GABA_γ2, and suggested that Nova1 and GABA_γ2 could be a novel predictor for HCC recurrence after curative resection.

Methods

Cells, animals and reagents

Two human HCC cell lines were used in this study. SMMC7721, Huh7 were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). SMMC7721 was cultured in RPMI medium 1640 (GIBCO, USA). Huh7 were cultured in DMEM supplemented with 10 % fetal bovine serum (GIBCO, Austria). Cells were cultured and passaged in 37 °C incubator with humidified atmosphere containing 5 % CO_2. Protocols of the establishment of cell lines to induce the Nova1 expression or silencing was summarized in previous study [6]. BALB/c nude mice were purchased from Shanghai Experimental Animal Centre, Chinese Academy of Science. Experimental animals were kept in the central animal facility of the Zhongshan Hospital affiliated to Fudan University and housed in laminar-flow cabinets under specific pathogen-free conditions. All studies on mice were conducted in accordance with the National Institute Guide for the Care and Use of Laboratory Animal. Goat anti-human Nova1 polyclonal antibody was purchased from LifeSpan Biosciences (Seattle, USA). Rabbit anti-human GABA_γ2 antibody was from Millipore. Rabbit anti-human GABA antibody was from Abcam. HRP affinipure goat anti-rabbit antibody was purchased from EarthOx, LLC (San Francisco, USA). DyLight 488 Affinipure Rabbit Anti-Goat IgG and DyLight 594 Affinipure Goat Anti-Rabbit IgG were purchased from Jackson. Mouse anti-GAPDH antibody and HRP-labeled goat anti-mouse antibody were purchased from Beyotime Institute of Biotechnology (Shanghai, China). ECL Western Blotting Substrate System was purchased from Pierce (Rockford, IL, USA).

Patients and specimens

Tissue microarrays used in this study were from Liver cancer institute, Zhongshan Hospital. (Shanghai Super Biotec company (ZL-LVC1604)). Eighty HCC patients who underwent curative resection, defined as complete macroscopic removal of the tumor, with clinicopathologic and follow-up data were enrolled in this study. None of the patients received anticancer therapy before sampling. The hepatocellular carcinoma diagnosis was established by history, physical examination, computer tomography, MRI (Magnetic Resonance Imaging), liver biopsy and subsequent histological and cytological analyses. Curative resection was defined as complete resection of tumor nodules and the surgical free margin of more than 5 mm by pathological examination; have no cancerous thrombus found in the portal vein(main trunk or two major branches), hepatic veins, or bile duct; and having no extra hepatic metastasis found.

All patients were followed every 3–4 months afterward. Most patients died of intrahepatic recurrence, distal metastasis, or complicated liver cirrhosis. All patients were monitored prospectively by serum AFP, abdomen ultrasonography (US), and chest X-ray every 1–6 months, according to the postoperative time. For patients with test results suggestive of recurrence, computed tomography (CT) and/or magnetic resonance and/or distal metastasis had occurred. Diagnosis of recurrence was based on typical imaging appearance in CT and/or MRI scan and an elevated AFP level. Overall survival (OS) was defined as the interval between the dates of surgery and death. Disease-free survival (DFS) was defined as the interval between the dates of surgery and recurrence or the last follow-up if no recurrence was observed. Clinical stages of tumors were determined according to the TNM classification system of International Union Against Cancer (Edition 6). Tumor differentiation is grade according to Edmondson - Steiner classification.

Ethics approval

All samples were coded anonymously in accordance with local ethical guidelines, as stipulated by the Declaration of Helsinki with written informed consent and a protocol approved by the Ethics Review Committee of Zhongshan Hospital of Fudan University, and every patient provided written informed consent before enrollment.

In vivo tumorigenicity

The HCC tumor xenografts animal models were established as follow: 1 × 10^6 Huh7 pSLIK empty vector, Huh7-shNova1 cells, SMMC7721 pSLIK empty vector
and SMMC7721-Nova1 cells were inoculated subcutaneously into the right side backs of the nude mice. For the tet-on system [6], Huh7-shNova1 and SMMC7721-Nova1 groups were further randomly divided into two groups, with (+Dox) or without (−Dox). (+Dox: Dox added into the mouse drinking water at a concentration of 1 mg/ml.) After the injection, the tumor size was estimated according to the formula: volume(mm$^3$) = 0.5 a$^2$ x b (a, major diameter of tumor; b, minor diameter perpendicular to the major one). Animals were feed for 4 weeks and in the end of feeding, animals were sacrificed. The tumor were removed for western blot analysis.

Immunochemical staining

The dissected tumor samples for immunohistochemistry were fixed in phosphate-buffered neutral formalin, embedded in paraffin, and cut into 5-μm-thick sections. Five-micron thick sections and tissue microarrays were fixed in 4 % formaldehyde and embedded in paraffin. Tissue samples were deparaffinized and rehydrated, followed by high-temperature antigen retrieval via microwave in 0.1 M citrate solution (pH 6.0) for 15 min. After blocked with 5 % normal goat serum at room temperature for 30 min, the sections were incubated with rabbit anti-human GABAAR antibody body at 4 °C overnight, and then incubated with appropriate secondary antibody at room temperature for 30 min, and finally immunostained by avidin-biotin complex technique using 3,3'-diaminobenzidine. Hematoxylin was used as a counterstain.

The total amount of positive cells in each section was evaluated by two independent investigators masked to clinical outcome and clinicopathologic data. Positive staining cells were observed by using one light microscope (Olympus BX51, Japan). The Friederichs scoring system was applied to analyze expression of in tumor and peritumoral tissues. The intensity of GABAAR2 staining was divided into four grades, score “0” for negative, “1” for light yellow, “2” for deep yellow, “3” for brown. GABAAR2 staining positive cells was further subgrouped into score “0” for less than 5 %, “1” for 6–20 %, “2” for 21–50 % and “3” for more than 51 %. The total score was defined as staining intensity and scales. Total score higher than 2 is considered as high expression, while under 2 as low expression.

Western blotting

Total cell or tissue lysates were generated and equal amount protein was subjected to 10 % SDS-PAGE gel, and then transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, USA). Membranes were blocked in blocking solution (50 mM Tri-HCl, 150 mM NaCl, 5 % (w/v) non-fat dry milk and 0.1 % Tween-20) at room temperature for 1 h, followed by incubation with Rabbit anti-human GABAAR antibody and rabbit anti-human GABA antibody at 4 °C overnight. After three times washing by 0.1 % TBS-Tween20, the membrane was incubated with secondary antibody at room temperature for 1.5 h, the blot were demonstrated by enzyme-linked chemiluminescence using a Fluor Chem FC2 chemiluminescent, fluorescent and visible light gel imaging system (Alpha Inotech, USA).

Co-immunoprecipitation (co-IP)

The cell-lysated proteins were precleared with 2 μg appropriate antibodies at 4 °C for 8 h, and then incubated with protein G-agarose (Roche) and antibodies at 4 °C overnight. For co-IP experiments using anti-Ub antibody, the cell lysates contained 1 % SDS and received prior heat treatment. The precipitates were pelleted, washed three times with the lysis buffer and analyzed by western blotting.

Statistical analysis

All values were expressed as mean ± standard deviation (SD). All statistical analyses were performed using the SPSS 18.0 (SPSS Inc., Chicago, IL). $\chi^2$-test or Fisher’s exact tests was used for the association of GABAAR2 expression with the clinicopathologic features. Student’s t test and independent sample t test were used for comparison between groups. Cumulative survival time was calculated by kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses were based on the Cox proportional hazard regression model. $P < 0.05$ considered as statistically significant.

Results

Nova1 promotes tumor growth in vivo

As shown in Fig. 1, for Huh7-shNova1, tumor volumes in +Dox group were smaller than that in −Dox group (31.25 ± 15.90 mm$^3$ vs. 287.10 ± 51.10 mm$^3$, $P < 0.05$). While for SMMC7721, the results showed that tumor of +Dox group grew faster and larger than −Dox (418.9 ± 185.6 mm$^3$ vs. 107.7 ± 78.83 mm$^3$, $P < 0.01$). These data indicated that Dox-induced Nova1 expression promotes subcutaneous HCC growth significantly (Fig. 1a-c).

Expression of GABAAR2 and GABA in hepatocellular carcinoma under the regulation of ectopic Nova-1

Later, immunohistochemical staining and western blot were carried out on tumor biopsy of nude mice. Study showed that down-regulation of Nova-1 accompanied with increased expression of GABAAR2 and GABA (Fig. 1d-e). The ectopic expression of Nova-1 retro-regulates the expression of GABAAR2 and GABA.
Fig. 1 (See legend on next page.)
GABA<sub>AR</sub>γ<sub>2</sub> interacts with Nova-1 in peripheral tumor tissues

Co-IP was used to verify the possibility of GABA<sub>AR</sub>γ<sub>2</sub> interacts with Nova1 outside the CNS in protein level. In Huh-7 cells, GABA<sub>AR</sub>γ<sub>2</sub> was easy to be detected through anti-Nova-1 antibody. Reciprocal co-IP experiments using anti-GABA<sub>AR</sub>γ<sub>2</sub> antibody indicated the existence of Nova-1. To verify the stringency of co-IP, parallel experiments were done in which co-IP antibody was replaced with isotype control antibody IgG or PBS. Meanwhile, control experiments showed negative results (Fig. 2).

Expression level of GABA<sub>AR</sub>γ<sub>2</sub> in HCC patients and its clinical significance

To explore the occurrence of GABA<sub>AR</sub>γ<sub>2</sub> expression in HCC, we first detected GABA<sub>AR</sub>γ<sub>2</sub> protein levels in tumor and peritumoral tissues. GABA<sub>AR</sub>γ<sub>2</sub> shows a mainly cytoplasmic staining on various normal liver cells and cancer cells (Fig. 3a). The percentage of GABA<sub>AR</sub>γ<sub>2</sub> positivity in the cancerous tissues was lower than that of para-cancerous tissues (35 %, 28/80 vs. 57.5 %, 46/80 respectively, \( P = 0.004 \)). As shown in Table 1, clinicopathologic variables such as vascular invasion \( (P = 0.014) \), tumor number \( (P = 0.016) \) and TNM \( (P = 0.008) \) stage were found to be associated with expression levels of intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression. None of the clinicopathologic variables were associated with peritumoral GABA<sub>AR</sub>γ<sub>2</sub> expression.

On univariate analysis of our data, several clinical factors including liver cirrhosis, vascular invasion, TNM stage and BCLC stage, showed prognostic significance for both OS and DFS (Table 2). Notably, intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression was a favorable predictor for OS and DFS (HR = 0.372 and 0.419, respectively, \( P < 0.01 \)). Clinicopathologic features showing significance by univariate analysis were adopted for further multivariate cox proportional hazards analyses (Table 3). Liver cirrhosis, Barcelona clinic liver cancer (BCLC) stage and intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression remained associated with OS \( (P = 0.01) \) and DFS \( (P = 0.007, 0.035 \text{ and } 0.002, \text{ respectively}) \) while Liver cirrhosis, TNM stage and intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression remained associated with DFS \( (P = 0.007, 0.035 \text{ and } 0.002, \text{ respectively}) \).

Since statistic results showed intratumoral GABA<sub>AR</sub>γ<sub>2</sub> was favorable predictor for recurrence, we then analyze this biomarker for early recurrence (metastasis after surgery ≤24 months) together with other clinical feathers that showed prognostic significance for TTR (Table 4). Liver cirrhosis and intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression were found to be an independent predictor for early recurrence \( (P = 0.046 \text{ and } 0.01) \).

Kaplan-Meier analysis and the log-rank test were performed to evaluate the effect of GABA<sub>AR</sub>γ<sub>2</sub> on survival (Fig. 3b). Patients with higher intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression had significantly longer OS (median 46 months) or DFS (median, 36 months) than patients with lower intratumoral GABA<sub>AR</sub>γ<sub>2</sub> expression. (median, OS: 14 months; DFS: 10 months, \( P = 0.001 \) and 0.002 respectively). Peritumoral GABA<sub>AR</sub>γ<sub>2</sub> was not associated with OS or DFS \( (P > 0.05) \).
Discussion and conclusions

The GABA_A receptor is an ionotropic receptor whose endogenous ligand is GABA, an inhibitory neurotransmitter in the central nervous system [12, 13]. By activation, the GABA_A receptor selectively conducts chloride ion influx through its pore, leading to hyperpolarization of the neuron, thus causing an inhibitory effect on neurotransmission [14, 15]. In humans, subunits of GABA_A receptor include six types α subunits(α1-α6), three βs(β1-β3), three γs(γ1-γ3), a δ, a ε, a θ and a π [16]. GABA_A receptors are most prevalent not only in central nervous system but also in peripheral tissues [8]. By studying the relationship between decreased hepatocyte membrane potential and proliferation of hepatocellular carcinoma, the expression of some receptors in the peripheral tumor such as GABA_A receptor-β3 [9], GABA_A receptor-α3 [10], and GABA_A Receptor family [11] were found to correlate with tumor growth. GABA_A Ry2 belongs to the GABA receptor family, however, among all these studies, the potential effects of GABA_A Ry2 on tumor proliferation has not been mentioned yet.

In the present study, we found that GABA_A Ry2 is expressed mainly in cytoplasm and little in nuclear of HCC by immunohistochemical staining. These findings corresponded with previous several reports proved the expression of GABA_A receptors in peripheral tumor tissues, such as receptor α2, β1, β3 and γ3 in human gastric cancer cell KATO III [17], receptor ε and π in human liver cancer tissue [9]. The expression of GABA_A Ry2 in tumor tissue is lower than that in paired peritumoral tissues which also be consistent with the research by Gerald Y. Minuk et al. [9]. By quantitative reverse transcription polymerase chain reaction (qRT-PCR), they found that GABA_A-β3 mRNA expression was decreased in tumor compared with adjacent nontumor tissue [9]. These two findings support previous descriptions of down-regulated or absent expression of GABA_A receptor in human malignant hepatocyte cell lines and GABA_A receptor β3 subunit expression inversely correlated with regenerative activity of human and rat liver [18, 19]. According to our previous study [6], we suppose that the potential mechanism of Nova1 as an oncogene for HCC may due to its interaction with GABA_A receptor γ2.

Before that, Dredge et al. found the splicing regulation of the GABA_A Ry2 subunit pre-mRNA exon E9 is
Table 1  Intratumoral and Peritumoral GABA<sub>γ2</sub> expression according to characteristics of HCC patients

| Characteristics                  | Intratumoral GABA<sub>γ2</sub> |                      |                      | Peritumoral GABA<sub>γ2</sub> |                      |
|----------------------------------|---------------------------------|----------------------|----------------------|-------------------------------|----------------------|
|                                  | low n = 52                       | high n = 28          | p values             | low n = 34                    | high n = 46          |
| Gender                           | Male 44                          | 24                   | 0.896                | 29                            | 39                   | 0.949                |
|                                  | Female 8                         | 4                    |                      | 5                             | 7                    |                      |
| Age(years)                       | ≤53 33                           | 14                   | 0.243                | 20                            | 17                   | 0.991                |
|                                  | >53 19                           | 14                   | 0.06                 | 14                            | 29                   | 0.533                |
| Preoperative AFP(ng/ml)          | ≤20 15                           | 14                   | 0.158                | 11                            | 18                   | 0.322                |
|                                  | >20 37                           | 14                   |                      | 23                            | 28                   |                      |
| HBsAg                            | Negative 11                      | 10                   | 0.176<sup>a</sup>    | 2                             | 4                    | 1.000<sup>a</sup>    |
|                                  | Positive 41                      | 18                   |                      | 27                            | 32                   |                      |
| Cirrhosis                        | No 2                             | 4                    | 0.176<sup>a</sup>    | 2                             | 4                    | 1.000<sup>a</sup>    |
|                                  | Yes 50                           | 24                   |                      | 32                            | 42                   |                      |
| Vascular invasion                | No 12                            | 14                   | 0.014                | 7                             | 19                   | 0.051                |
|                                  | Yes 40                           | 14                   |                      | 27                            | 27                   |                      |
| Number                           | Single 36                        | 26                   | 0.016                | 25                            | 37                   | 0.465                |
|                                  | Multiple 16                      | 2                    |                      | 9                             | 9                    |                      |
| Size(cm)                         | <5 16                            | 13                   | 0.165                | 12                            | 16                   | 0.962                |
|                                  | ≥5 36                            | 15                   |                      | 22                            | 30                   |                      |
| Tumor Differentiation            | I-II 7                           | 4                    | 1.000<sup>a</sup>    | 4                             | 7                    | 0.751                |
|                                  | III-IV 45                        | 24                   |                      | 30                            | 39                   |                      |
| TNM stage                        | I 11                             | 14                   | 0.008                | 7                             | 18                   | 0.077                |
|                                  | II-III 41                        | 14                   | 0.013                | 27                            | 28                   |                      |
| BCLC stage                       | A 5                              | 6                    | 0.18                 | 3                             | 8                    | 0.338                |
|                                  | B/C 47                           | 22                   |                      | 31                            | 38                   |                      |

<sup>a</sup>Fisher’s exact test for all other analyses

---

Table 2  Univariate analyses of factors associated with survival and recurrence

| Variables                        | OS Hazard ratio (95 % CI) | P   | DFS Hazard ratio (95 % CI) | P   |
|----------------------------------|---------------------------|-----|---------------------------|-----|
| Sex(male vs female)              | 1.126 (0.525–2.416)       | 0.76| 1.483 (0.844–2.608)       | 0.171|
| Agey(≥53 vs. < 53)               | 1.609 (0.902–2.874)       | 0.107| 0.802 (0.361–1.781)       | 0.588|
| Preoperative AFP, ng/ml (>20 vs. ≤20) | 1.320 (0.721–2.415)   | 0.369| 1.390 (0.778–2.485)       | 0.266|
| HBsAg (negative vs.positive)     | 1.175 (0.598–2.311)       | 0.639| 1.040 (0.563–1.925)       | 0.899|
| Liver cirrhosis (yes vs. no)     | 3.303 (1.290–8.455)       | 0.013| 2.878 (1.121–7.385)       | 0.028|
| Vascular invasion                | 1.976 (1.004–3.891)       | 0.049| 0.922 (0.523–1.625)       | 0.78  |
| Tumor size, cm (>5 vs. ≤5)       | 1.107 (0.609–2.014)       | 0.738| 0.818 (0.468–1.429)       | 0.48  |
| Tumor number (multiple vs.single) | 1.718 (0.886–3.330)       | 0.109| 1.265 (0.646–2.475)       | 0.493|
| Tumor differentiation (I-II vs.III-IV) | 1.215 (0.566–2.608) | 0.618| 0.971 (0.472–1.999)       | 0.937|
| TNM stage (III vs.II)            | 2.253 (1.209–4.199)       | 0.011| 2.137 (1.177–3.880)       | 0.013|
| BCLC stage (C vs. A/B)           | 1.976 (1.004–3.891)       | 0.049| 0.922 (0.523–1.625)       | 0.78  |
| Intratumoral GABA<sub>γ2</sub>   | 0.372 (0.203–0.683)       | 0.001| 0.419 (0.232–0.755)       | 0.004|
| Peritumoral GABA<sub>γ2</sub>    | 1.302 (0.719–2.355)       | 0.384| 1.503 (0.850–2.657)       | 0.161|
disrupted in mice lacking Nova1 [7]. Transfection of pNova1-plasmid caused a dose-dependent increase in E9 inclusion in 293 T cells [7]. In CNS, the interaction between Nova1 and GABA A Rγ2 is delineated in the way that Nova1 acts directly on GABA A Rγ2 pre-mRNA by a direct action on clustered YCAY (Y is a pyrimidine) intonic repeats [7]. In our study, Co-IP experiments proved the protein level interaction between GABA ARγ2 and Nova1 in HCC. Furthermore, western blot showed down-regulation of Nova1 accompanied with increased expression of GABA ARγ2 and GABA. The ectopic expression of Nova1 restro-regulates the expression of GABA ARγ2 in HCC. The ectopic expression of Nova1 restro-regulates the expression of GABA ARγ2 and GABA. It is unclear why upregulation of Nova1 did not turn out to be an increase expression of GABA ARγ2 in tumor tissue, but restro-regulates the expression of GABA ARγ2 instead. Some mechanisms could partly explain the reason. (1) Dredge et al. found that Nova1 binds with high affinity to the wild-type but not the mutated sequence. Maybe the mutation of these YCAY repeats to YAAY in HCC completely abolished Nova1’s effect on splicing thus leading to the decrease expression of GABA ARγ2 [20, 21]. (2) Gerald Y. Minuk et al. [9] found that the methylation status of GABA ARγ2 promoter in HCC resulted in attenuated downstream GABA A receptor β3 gene expression. Therefore, the change of the methylation status of the upstream GABA ARγ2 promoter in HCC may also exist. (3) Another view point proposed by Buckanovich et al. is that the interference with the RNA-binding activity of Nova1 may be an immune-mediated rather than the genetic mechanisms. Auto-antibodies due to ectopic expression of Nova1 protein abrogate the Nova-1-RNA interaction via immune-mediated mechanism leading to down-regulation of GABA ARγ2 [20]. Since no further evidence to prove the existence of mutation sequence, nor further analysis of the GABA ARγ2 promoter methylation in HCC, nor experiments had been carried out to test the abrogation of auto-antibody of Nova1, additional studies to elucidate the mechanisms involved is needed.

Survival analyses showed that univariate and multivariate analysis disclosed the relationship of intratumoral GABA ARγ2 and OS or DFS in HCC patients that intratumoral GABA ARγ2 was an independent prognostic factor for OS and DFS. Moreover, intratumoral GABA ARγ2 strongly correlated to HCC early recurrence. Some recognized factors such as BCLC stage, TNM stage vascular invasion were not associated with early recurrence, mostly likely because of the limited number of patients enrolled in the study. More HCC patients and longer follow-up study are still requied to verify our results in future study.

In conclusion, we demonstrated an decreased expression of GABA ARγ2 in HCC compared to adjacent normal tissue. Intratumoral GABA ARγ2 was an independent prognostic factor for OS and DFS. Nova1 interacts with GABA ARγ2 not only in CNS but also in HCC. Over-expression of Nova1 restro-regulates the expression of GABA ARγ2 in HCC. Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABA A Receptor γ2. A better understanding of the mechanism of RBP Nova1 for HCC progression might facilitate the design of more effective immunotherapies or gene therapy for hepatocellular carcinoma.

### Table 3

| Factor                     | Hazard ratio (95 % CI) | P   |
|----------------------------|------------------------|-----|
| Liver cirrhosis (yes vs. no) | 3.711 (1.448–9.510)    | 0.006|
| Vascular invasion (yes vs.no) | NS                     |     |
| TNM stage (II-III vs. I)     | NS                     |     |
| BCLC stage (B/C vs. A)       | 2.591 (1.251–5.365)    | 0.01 |
| Intratumoral GABAARγ2 (high vs.low) | 0.309 (0.163–0.588)    | <0.001|

### Table 4

| Factor                        | Early recurrence | Multivariate |
|-------------------------------|-----------------|--------------|
|                               | Univariate P    | HR (95 % CI) | P   |
| Liver cirrhosis (yes vs. no)  | 0.039           | 2.610 (1.016–6.706) | 0.046 |
| Vascular invasion (yes vs.no) | 0.197           | NS           |     |
| TNM stage (II-III vs. I)      | 0.011           | NS           |     |
| BCLC stage (B/C vs. A)        | 0.197           | NS           |     |
| Intratumoral GABAARγ2 (high vs.low) | 0.022 | 0.41 (0.208–0.811) | 0.01 |
| Peritumoral GABAARγ2 (High vs. Low) | 0.087 | NS |     |
Abbreviations

AFP: Alpha fetoprotein; BCLC: Barcelona clinic liver cancer; Ct: Confidence interval; CNS: Central nervous system; DFS: Disease free survival; GABA<sub>x</sub>-y-aminobutyric acid<sub>x</sub>; GABA<sub>α</sub>2: GABA<sub>α</sub> Receptor-y2; HCC: Hepatocellular carcinoma; NS: Not significant; OS: Overall survival; PBS: Phosphate-buffered saline; qRT-PCR: Quantitative reverse transcription polymerase chain reaction; RBP: RNA-binding proteins; TNM: Tumor-node-metastasis; TTR: Time to recurrence

Acknowledgments

The authors would like to thank the members of Prof. Xizhong Shen’s Laboratory for their helpful discussion and critical reading of the manuscript.

Funding

This study was supported by National Nature Science Foundation of China (No.81000968, No. 81101540, No. 81101637, No. 81172273, No. 81272388, No. 81301820, No. 81472673), Doctoral Fund of Ministry of Education of China (20120071110058), The National Clinical Key Special Subject of China.

Availability of data and materials

All relevant data are within the paper.

Authors’ contributions

All authors read and approved the final manuscript.

Competing interests

YAZ, HNL, DJY performed experiments described in this study. XZS, TTL contributed to experimental design. YAZ, HNL contributed to manuscript writing. The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All samples were coded anonymously in accordance with local ethical guidelines, as stipulated by the Declaration of Helsinki with written informed consent and a protocol approved by the Ethics Review Committee of Zhongshan Hospital of Fudan University with the following reference number Y2016-151, and every patient provided written informed consent before enrollment.

Author details

1Department of Hematology, Zhongshan Hospital of Fudan University, Zhongshan Hospital, No.180 Fenglin Road Xuhui District, Shanghai, China. 2Department of Gastroenterology, Zhongshan Hospital of Fudan University, Zhongshan Hospital, No.180 Fenglin Road Xuhui District, Shanghai, China. 3Key Laboratory of Medical Molecule Virology, Ministry of Education and Health, Shanghai Institute of Liver Diseases, Zhongshan Hospital, No.180 Fenglin Road Xuhui District, Shanghai, China.

Received: 9 June 2016 Accepted: 27 September 2016

Published online: 12 October 2016

References

1. Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin. 2012(62):394–9.
2. Jeng YM, Chiang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC. RNA-binding protein insulin-like growth factor II mRNA-RNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma[J]. Hepatology. 2008;48(4):1118–27.
3. Iida M, Izuka N, Tsunedomi R, Tsutsui M, Yoshida S, Maeda Y, Tokuhiya S, Sakamoto K, Yoshimura K, Tamesa T, Oka M. Overexpression of the RD RNA-binding protein in hepatitis C virus-related hepatocellular carcinoma[J]. Oncol Rep. 2012;28(2):728–34.
4. Qian HL, Chen SH, Peng XX. Significance of a novel fetal RNA-binding protein p62 expression in hepatocellular carcinoma[J]. Zhonghua Bing Li Xue Za Zhi. 2003;32(4):329–32.
5. Buckanovich RJ, Posner JB, Darnell RB. Nova, the oncofetal antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system[J]. Neuron. 1993;11(4):657–72.
6. Zhang YA, Zhu JM, Yin J, Tang WQ, Guo YM, Shen XZ, Liu TT. High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma[J]. PLoS One. 2014;9(3):e90955.
7. Dredge BK, Darnell RB. Nova regulates GABA<sub>α</sub> receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer[J]. Mol Cell Biol. 2003;23(13):4687–700.
8. Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H, GABA and GABA receptors in the central nervous system and other organs[J]. Int Rev Cytol. 2002;213:1–47.
9. Minuk GY, Zhang M, Gong Y, Minuk L, Dienes H, Pettigrew N, Kew M, Lipschitz J, Sun D. Decreased hepatocyte membrane potential differences and GABA<sub>α</sub>beta2 expression in human hepatocellular carcinoma[J]. Hepatology. 2007;45(3):735–45.
10. Liu Y, Li YH, Guo FJ, Wang JJ, Sun RL, Hu JY, Li GC. Gamma-aminobutyric acid promotes human hepatocellular carcinoma growth through overexpressed gamma-aminobutyric acid A receptor alpha 3 subunit[J]. World J Gastroenterol. 2008;14(7):7175–82.
11. Wang T, Huang W, Chen F. Backfem, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo[J]. Life Sci. 2008;82(9–10):536–41.
12. Richter L, de Graaf C, Sieghart W, Zierer A, Berendt R. Value and limitations of transmembrane electrocardiography in assessment of mitral valve prosthesis[J]. Circulation. 1991;83(6):1956–68.
13. Olsen RW, Sieghart W, GABA A receptors: subtypes provide diversity of function and pharmacology[J]. Neuropharmacology. 2009;56(1):141–8.
14. Maemura K, Shinashi N, Sakagami K, Kawakami K, Inoue T, Murano M, Watanabe M, Otsuki Y, Proliferative effects of gamma-aminobutyric acid on the gastric cancer cell line are associated with extracellular signal-regulated kinase 1/2 activation[J]. J Mol Graph Model. 2007;25(6):721–30.
15. Khandheria BK, Seward JB, Oh JK, Freeman WK, Nichols BA, Sink LJ, Miller FJ, Tajik AJ. Value and limitations of transesophageal echocardiography in assessment of mitral valve prosthesis[J]. Circulation. 1991;83(6):1956–68.
16. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology[J]. Neuropharmacology. 2009;56(1):141–8.
17. Minuk GY, Zhang M, Gong Y, Minuk L, Dienes H, Pettigrew N, Kew M, Lipschitz J, Sun D. Decreased hepatocyte membrane potential differences and GABA<sub>α</sub>beta2 expression in human hepatocellular carcinoma[J]. Hepatology. 2007;45(3):735–45.
18. Sun D, Gong Y, Kojima H, Wang G, Ravinsky E, Zhang M, Minuk GY. Increasing cell membrane potential and GABAergic activity inhibits malignant hepatocyte growth[J]. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G12–9.
19. Efthimiou F, Gong Y, Zhang M, Minuk G. Identification of gamma-aminobutyric acid receptor subunit types in human and rat liver[J]. Am J Physiol Gastrointest Liver Physiol. 2000;279(4):G205–9.
20. Buckanovich RJ, Yang YY, Darnell RB. The oncofetal antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies[J]. J Neurosci. 1996;16(3):1114–21.